CR20180044A - Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr - Google Patents

Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr

Info

Publication number
CR20180044A
CR20180044A CR20180044A CR20180044A CR20180044A CR 20180044 A CR20180044 A CR 20180044A CR 20180044 A CR20180044 A CR 20180044A CR 20180044 A CR20180044 A CR 20180044A CR 20180044 A CR20180044 A CR 20180044A
Authority
CR
Costa Rica
Prior art keywords
oxo
methylene
methyl
inhibitor
thyzolidine
Prior art date
Application number
CR20180044A
Other languages
English (en)
Inventor
Michaël Frank Burbridge
Anne Jacquet-Bescond
Valérie Cattan
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20180044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20180044A publication Critical patent/CR20180044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

Asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1H-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidina-2,4-diona de fórmula (I): o uno de sus isómeros Z o E y/o sales de adición a un ácido o a una base farmacéuticamente aceptable, y un inhibidor de tirosina quinasa del receptor del factor de crecimiento epidérmico humano (EGFR)
CR20180044A 2015-07-31 2016-07-29 Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr CR20180044A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1557412A FR3039401B1 (fr) 2015-07-31 2015-07-31 Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
PCT/FR2016/051976 WO2017021634A1 (fr) 2015-07-31 2016-07-29 Association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1 h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1 h-l ndol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Publications (1)

Publication Number Publication Date
CR20180044A true CR20180044A (es) 2018-04-03

Family

ID=55299545

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180044A CR20180044A (es) 2015-07-31 2016-07-29 Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr

Country Status (40)

Country Link
US (1) US20170027952A1 (es)
EP (1) EP3124025B1 (es)
JP (2) JP2017061445A (es)
KR (1) KR101822492B1 (es)
CN (1) CN106397427A (es)
AR (1) AR105527A1 (es)
AU (1) AU2016206300A1 (es)
BR (1) BR102016017404A2 (es)
CA (1) CA2936904C (es)
CL (1) CL2018000256A1 (es)
CO (1) CO2018000953A2 (es)
CR (1) CR20180044A (es)
CU (1) CU20180013A7 (es)
CY (1) CY1120792T1 (es)
DK (1) DK3124025T3 (es)
EA (1) EA032217B1 (es)
EC (1) ECSP18003671A (es)
ES (1) ES2671133T3 (es)
FR (1) FR3039401B1 (es)
HR (1) HRP20180760T1 (es)
HU (1) HUE037632T2 (es)
IL (1) IL257232A (es)
LT (1) LT3124025T (es)
MA (1) MA39693B1 (es)
MD (1) MD3124025T2 (es)
ME (1) ME03052B (es)
MX (1) MX366748B (es)
NO (1) NO3124025T3 (es)
PE (1) PE20190350A1 (es)
PH (1) PH12016000248A1 (es)
PL (1) PL3124025T3 (es)
PT (1) PT3124025T (es)
RS (1) RS57057B1 (es)
RU (1) RU2695362C2 (es)
SG (1) SG10201605664SA (es)
SI (1) SI3124025T1 (es)
SV (1) SV2018005615A (es)
TN (1) TN2018000028A1 (es)
TW (1) TWI623315B (es)
WO (1) WO2017021634A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101956978B1 (ko) * 2015-05-18 2019-03-12 주식회사 케이티 시스템 정보 송수신 방법 및 그 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2068880T3 (da) * 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
AR065519A1 (es) * 2007-03-01 2009-06-10 Vernalis Res Ltd Sales de adicion de acido, hidratos y polimorfos de la etil - amida del acido 5- (2,4- dihidroxi -5- isopropil - fenil )-4-(4- morfolin-4-il-metil - fenil ) - isoxasol-3- carboxilico y formulaciones que comprenden estas formas
JPWO2008108386A1 (ja) * 2007-03-05 2010-06-17 協和発酵キリン株式会社 医薬組成物
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5945863B2 (ja) * 2012-01-06 2016-07-05 国立大学法人高知大学 腎細胞がん治療剤
US9925240B2 (en) * 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
JP2017502055A (ja) * 2014-01-07 2017-01-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗癌活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体のゲフィチニブとの併用
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer

Also Published As

Publication number Publication date
NO3124025T3 (es) 2018-07-28
FR3039401B1 (fr) 2018-07-13
SG10201605664SA (en) 2017-02-27
WO2017021634A1 (fr) 2017-02-09
PL3124025T3 (pl) 2018-06-29
MA39693A (fr) 2017-02-01
DK3124025T3 (en) 2018-06-06
ES2671133T3 (es) 2018-06-05
SI3124025T1 (en) 2018-04-30
CO2018000953A2 (es) 2018-07-10
JP2017061445A (ja) 2017-03-30
EA201600507A2 (ru) 2017-02-28
EA032217B1 (ru) 2019-04-30
EP3124025B1 (fr) 2018-02-28
BR102016017404A2 (pt) 2017-02-07
TN2018000028A1 (fr) 2019-07-08
CU20180013A7 (es) 2018-05-08
ECSP18003671A (es) 2018-03-31
RU2016131395A3 (es) 2018-06-08
TW201711686A (zh) 2017-04-01
CN106397427A (zh) 2017-02-15
EA201600507A3 (ru) 2017-03-31
RU2695362C2 (ru) 2019-07-23
AR105527A1 (es) 2017-10-11
HRP20180760T1 (hr) 2018-06-15
PT3124025T (pt) 2018-04-09
US20170027952A1 (en) 2017-02-02
PH12016000248A1 (en) 2018-01-22
SV2018005615A (es) 2018-05-14
KR20170015218A (ko) 2017-02-08
RU2016131395A (ru) 2018-02-02
CA2936904A1 (fr) 2017-01-31
ME03052B (me) 2018-10-20
RS57057B1 (sr) 2018-05-31
EP3124025A1 (fr) 2017-02-01
LT3124025T (lt) 2018-03-26
KR101822492B1 (ko) 2018-01-29
FR3039401A1 (fr) 2017-02-03
MX2016009743A (es) 2017-03-03
CY1120792T1 (el) 2019-12-11
MX366748B (es) 2019-07-23
HUE037632T2 (hu) 2018-09-28
MA39693B1 (fr) 2018-07-31
CL2018000256A1 (es) 2018-04-06
CA2936904C (fr) 2018-12-04
MD3124025T2 (ro) 2018-06-30
AU2016206300A1 (en) 2017-02-16
IL257232A (en) 2018-03-29
TWI623315B (zh) 2018-05-11
PE20190350A1 (es) 2019-03-07
JP2019163306A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
BR112018002071A2 (pt) compostos heteroarílicos ou arílicos fundidos bicíclicos
NI201000059A (es) Inhibidores de la cinasa c-fms.
PE20191655A1 (es) Combinaciones farmaceuticas
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
AR090357A1 (es) Sales de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
CR20180044A (es) Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
DOP2011000398A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)
CO7160116A2 (es) Derivados de pirimidinona como agentes antimalaricos
MY183197A (en) New salt of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its prepration process, and formulations containing it
MA43157A (fr) Sels de 1-(4-(2-((1-(3,4-difluorophényl)-1h-pyrazol-3-yl)méthoxy)éthyl) pipérazin-1-yl)éthanone
AR106542A1 (es) Inhibidor del receptor p2x7
AR106038A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
TH171927A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
CL2007003602A1 (es) Procedimiento de preparacion de 7-fluoro-4-[2-[4-(tieno[3,2-c]piridin-4-il)piperazin-1-il]etil]-1,2-dihidroquinolein-1-acetamida; uno de los compuestos intermediarios usados; y el procedimiento de preparacion de dicho intermediario.
ECSP11011547A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3